Illumina (ILMN) sees Significant Insider Selling Continuing

Friday, September 01, 2017 10:15 PM ET

Illumina (ILMN) sees Significant Insider Selling Continuing

A notable insider sale of the shares of Illumina was disclosed in a form 4 document filed with the SEC today, showing — Michel Bouchard, Officer — sold 5,390 shares in the company having a market value of approximately $1,089,370. There have been 4 insiders with buy/sell transactions in the past 90 days prior to this filing. All of these trades have been sales resulting in the sale of 14,865 company shares. Adding the most recent activity to this 90-day history indicates insider trades have seen net sales of 20,255 shares and have averaged 4,051 shares per transaction over this time period.

The number of insider buy/sell trades at Illumina is above that of the 88 peer company average over the last 90-day period. The Advanced Medical Equipment & Technology peer group saw 91 buy/sell trades during this period for an average of 1.0 transactions per company. However, the number of shares traded per transaction by Illumina insiders is lower than its peers. Within the peer group there were 524,542 shares purchased and 860,473 shares sold with company insiders selling 3,692 shares on average over this time period.

In determining significant insider buying and selling, trades reported to the SEC that involve awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers have been eliminated in data sourced to evaluate and write this story.

Using proprietary artificial intelligence methods, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at Copyright 2017 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.